DOI 10.1016/j.urolonc.2025.05.016
Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
Аннотация
BACKGROUND
Enfortumab vedotin (EV) is an antibody-drug conjugate that binds nectin-4, a cell-adhesion molecule highly expressed in urothelial carcinoma (UC) and epidermal keratinocytes. Dermatologic events have become important EV-related toxicities in clinical trials and observational studies. We conducted a systematic review and meta-analysis on dermatological toxicity in UC patients treated with EV.
METHODS
We systematically searched PubMed, Cochrane, and Embase for clinical trials (CT) and observational studies reporting EV-related cutaneous toxicities in UC patients. We investigated all-grade and grade ≥ 3 treatment-related adverse events (TRAE) and severe cutaneous adverse reactions (SCAR) in UC patients. The outcomes were presented as overall incidence rates and 95% confidence intervals (95% CI). Statistical analyses were performed using R software.
RESULTS
30 studies comprising 2,554 participants were included, of which 72% (n = 1,845) were male. In a pooled analysis, all-grade skin reaction rate was 49% (95% CI 42%-56%), and grade ≥ 3 events were observed in 10% (95% CI 8%-13%) of cases. The incidence of all-grade and grade ≥ 3 SCAR was 19% (95% CI 16%-23%) and 5% (95% CI 3%-7%), respectively. The frequency of alopecia, pruritus, and dry skin were as follows: 29%, 26%, and 22%. The incidence of all-grade rash was 27%, with maculopapular rash (19%), and erythematous rash (6%) as the most common types.
CONCLUSIONS
To our knowledge, this is the first meta-analysis to characterize EV-related dermatological toxicities. While most cases are manageable, patients on EV should be closely monitored for cutaneous AEs to prevent serious complications and to maintain treatment efficacy.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.